Get started

Breakoutstocks

Clean science falling wedge breakout on weeklyBuy clean science for longerterm ABOUT Incorporated in 2003, Clean Science and Technology Ltd is one of the leading chemical manufacturers globally. It manufactures functionally critical specialty chemicals such as Performance Chemicals (MEHQ, BHA, and AP), Pharmaceutical Intermediates (Guaiacol and DCC), and FMCG Chemicals (4-MAP and Anisole). KEY POINTS Product Segments & Revenue split FY22 Performance chemicals (70%): 4 key products are MEHQ, BHA, AP and TBHQ. Geography-wise Revenue Classification Leading Manufacturer of Green Chemistry Green chemistry is an emerging focus among manufacturing industries that minimizes pollution at a molecular level and Clean science works on developing eco-friendly and sustainable manufacturing processes of specialty and fine chemicals and is one of the global leaders in its key products including monomethyl ether of hydroquinone, butylated hydroxyanisole, anisole, and 4-MAP, besides in other key products including guaiacol and DCC Product Application Company's products include Anisole, MEHQ, Guaiacol, MAP, BHA, Ascorbyl Palmitate. These are used as key starting level materials, as inhibitors or as additives by diverse Industries such as Textiles, FMCG, Agriculture, Personal Care, and many others. Its Key customers include Bayer AG, SRF Ltd, Gennex Laboratories, Nutriad International NV and Vinati Organics. **International Footprints ** The company supplies its products to manufacturers and distributors in India as well as overseas markets i.e. China, Europe, USA, Korea, Taiwan, and Japan. Bayer AG, Genex Laboratories Limited, Nutriad International NV, SRF Limited, Vinati Organics are a few of its customers. In FY 22, it generated 70 % of revenues through export outside India Manufacturing Facilities It has 3 certified production facilities in India strategically located at Kurkumbh (Maharashtra), in close proximity to the JNPT port from where it exports the majority of products. Each facility has an on-site R&D unit, quality control department, warehouse, and effluent treatment system. CAPEX In FY22, co. incurred ₹140 Crores, capex towards unit three primarily. All capex was funded from internal accruals. Majority Capex was undertaken at unit three where they commissioned two plants, PBQ and TBHQ, which are newer products. Doubled anisole capacity and increased BHA capacity by 50%. Increased capacities of MEHQ and Guaiacol by 50% and the plant was commissioned in April 2022. They are also in the process of doubling PBQ capacity,completion expected in the second half FY23. R&D Breakthrough in FY21 The Co. successfully developed key products in HALS series using in-house R&D capabilities and has become the first Indian company to develop HALS series which find application in diverse end industries including polymerization inhibitor, water treatment, paint industry, coatings industry, etc. The company plans to commercialize this product by H2 FY2023. Revenue Concentration In FY22, revenue from a single customer accounted for 12.5% of the total revenues. IPO Details The Company got listed on Jul 19, 2021, the IPO size of the company was 1546 Cr of which the entire issue was an Offer for sale. Incorporation of subsidiary During FY22, co. incorporated a new WOS to manufacture speciality chemicals including the HALS series under the name “Clean Fino-Chem Limited” with an initial Capital of 10 lakhs Subsequently, the Company made additional equity investments of 55 crores in CFCL. The greenfield Capex on an acquired 34-acre land parcel will be undertaken through this subsidiary.
NSE:CLEANLong
by shah43nirav
Transpek done breakout with volumes Buy transpek with sl 1430 closing basis cmp 1840 add till 1600 if breakout retesting stock do tgt 2050-2400-3000 also possible ABOUT Incorporated in 1965, Transpek Industry Limited is into the manufacturing and export of a range of chemicals servicing the requirements of customers from a diverse range of industries including Textiles, Pharmaceuticals, Agrochemicals, Advanced Polymers, etc. KEY POINTS Product Portfolio The Co. manufactures chlorinated products for the supply of intermediates and specialty chemicals suitable for multiple applications consisting of Specialty Chemicals, Surfactants, Agrochemicals, Dyes, Polymers, and Pharma. Market Position The Co. is one of the largest players in Acid Chlorides that are used in making such polymers and plastics and is focused on maintaining and growing its business in this segment. New Products The Co. has introduced four new products under the chlorination chemistry. It also has few new products under pipeline in chlorine and non-chlorine chemistry, which will help the Co. to seize the upcoming opportunity in multi-synthesis products. Revenue Distribution based on Application- FY22 Polymer - 60% Pharma - ~13% Specialty - 13% Others - ~14% Manufacturing Facility The Co. has its plant located in Ekalbara in Gujarat. It has dedicated multipurpose and multiproduct plants spread over 100 acres with a total production capacity of 66,000 MTPA. It also has a facility to take up contract manufacturing and a job work facility for its customers to provide them with economically viable solutions. Capex The Co has primary approval for adding 450 metric tons p.m of alkyl and acid chloride on premise at Ekalbara (Gujarat), but it can only add up to 250 metric tons due to the current effluent or emission level norms. It has undertaken a Capex of Rs.35 Cr to replace an old plant for one existing product where demand is expected to be higher. The new plant will add capacity to the tune of 70% of the current plant capacity and will also allow the production of other products. Geographical Presence The Co. is amongst the leading global exporters from India since 1986 having long term relations with leading global chemical giants. It has a presence across 14 countries. Geography Wise Revenue Split FY22 North America: ~61% India: ~24% Europe: ~11% Rest of the World: ~4% Project on Hold Due to uncertainties in the aftermath of COVID-19, the new project undertaken through a wholly owned subsidiary of the Company Transpek Creative Chemistry Pvt Ltd, with investments of Rs. 120 Cr., has been put on hold and later decided not to pursue the project further. R&D The Co. spent 0.77% of total revenue in R&D in FY22 vs 1.21 % in FY21. Focus The Co. is focusing on broadening the market, value-added products and working closely with the current and potential customers. It has been working on expanding its customer base and geographical spread which will add to the overall business volumes in the coming period. Further, it is adding more Acid Chlorides and focusing on commercializing other products that are under development which will help to reduce concentration on Acid Chlorides.
BSE:TRANSPEKLong
by shah43nirav